Lung Cancer, Exercise and Force Development

Lung Cancer Clinical Trial

Official title: Exercise in Lung Cancer Patients - Specific Training, Muscle Mass and Force Development

Status Recruiting

Clinical Trial Summary

This study evaluates the effectiveness of a supervised one-leg resistance training program in patients with inoperable lung cancer with the primary outcome being rate of force development.

Study design: Single center, two-armed, parallel-group, randomized controlled trial. The primary outcome being rate of force development after 12 weeks of progressive resistance training.

Clinical Trial Description

Muscular dysfunction and sarcopenia are known phenomena in cancer patients, and patients experience reduced muscle function and muscle loss regardless of cancer type or stage. Studies indicate that there are a number of cancer-specific and non-cancer-specific factors that influence muscle dysfunction, such as age, poor nutrition, physical inactivity, cancer pathology and treatment preparations. The decreased muscle function can ultimately lead to cachexia, typically seen in stage III - IV lung cancer patients.

Previous studies have focused on 1-RM tests, muscle mass and functionality as outcomes. However, a central aspect of functionality in lung cancer patients may be the muscle's ability to develop force in a short time. The present study therefore has rate of force development as a primary outcome with muscle mass and functionality as supporting outcomes. In addition, the patients in this study will perform one-leg resistance exercise with the other leg as the control leg. This will eliminate the interpersonal bias normally seen in randomized controlled trials. ;

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

• NCT number: NCT05778136
• Study type: Interventional
• Source: Rigshospitalet, Denmark
• Contact: Morten Quist, ph.d.
• Phone: +4535457335
• Email: morten.quist@regionh.dk
• Status: Recruiting
• Phase: N/A
• Start date: March 31, 2023
• Completion date: December 1, 2023